News | Stents | August 21, 2019

Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025

New drug discoveries, continued research into bioresorbable stents expected to drive market growth

Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025

August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the global cardiovascular stents market, predicts Fortune Business Insights in a new study.

The study is titled, “Cardiovascular Stents Market: Global Market Analysis, Insights and Forecasts, 2018 – 2025”. As per Fortune Business Insights, the market is prognosticated to exhibit a 6.6 percent compound annual growth rate (CAGR).

In terms of stent type, the drug-eluting stents (DES) segment is expected to hold the dominant position in the market. This dominance is attributable to key companies introducing next-generation drugs for DES, and is likely to continue in the coming years. 

With respect to end users, the hospitals segment holds dominance in the global market as it registers the highest consumption of cardiovascular stents.

The global market derives growth from a number of factors such as increasing focus on research and development (R&D). Besides this, increasing regulatory approvals from organizations such as the U.S. Food and Drug Administration (FDA) have contributed significantly to the global cardiovascular stents market.  

Furthermore, newer drug discoveries as a result of emphasis on R&D have favored the growth of the global cardiovascular stents market and are likely to boost the market in the coming years, backed by contributions from government as well as private organizations. 

In 2017, coronary stenting procedures were the most common treatment among cardiovascular patients, with a market share of 66.9 percent. The rising number of cardiovascular diseases worldwide is expected to drive the global market, as per analysts at Fortune Business Insights.

Besides this, huge investments made by market players in research and development on environmental and bioresorbable coronary stents is also anticipated to boost the market. 

Generally unhealthy lifestyles and irregular eating habits have led to an increase in the prevalence of health-related concerns, including chronic diseases such as diabetes, obesity and heart disorders. The surging cases of heart disorder is continuously fueling the demand for new cardiovascular treatments including angioplasty, which will ultimately increase the demand for cardiovascular stents, according to the report.

However, the market may face challenges due to the presence of alternative treatment methods for vascular diseases. The complexity of cardiovascular stent implantation may cause patients to opt for other treatment options and this may restrict growth in the market. Besides this, high-profile incidents of product recalls and failures may also hamper the market in future, according to Fortune Business Insights. Nevertheless, the emerging market for cardiovascular stents and their rapid ascent is likely to boost growth opportunities for the market in the long run. 

The North American market has emerged as the dominant market segment worldwide as of 2017. This is mainly due to the presence of better medical facilities and skilled professionals in the developed nations of Canada and the U.S, according to the report. North America is likely to remain dominant in the coming years as well, on account of ongoing clinical trials on novel stents in the U.S. and various regulatory approvals for cardiovascular stents. 

At the same time, the Asia Pacific is projected to show the most growth during the report period on account of improved distribution of cardiovascular stents in emerging economies such as China and India. In order to improve their accessibility, price capping of stents has been introduced in these developing nations and this will help the market gain momentum.

You can read the full report here.

For more information: www.fortunebusinessinsights.com

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init